Company Filing History:
Years Active: 2013
Title: Gregory Everett Amidon: Innovator in Sustained-Release Pharmaceuticals
Introduction: Gregory Everett Amidon, based in Portage, MI, has made significant contributions to the field of pharmaceutical sciences. He is best known for his innovation in the development of a sustained-release tablet composition of pramipexole, a medication primarily used in the treatment of Parkinson's disease.
Latest Patents: Gregory Amidon holds a patent for a "Sustained-release tablet composition of pramipexole." This innovative pharmaceutical composition features a water-soluble salt of pramipexole, which is dispersed in a matrix containing a hydrophilic polymer and starch. The unique formulation ensures a tensile strength of at least about 0.15 kN at a solid fraction representative of the tablet, enhancing its effectiveness and usability for patients.
Career Highlights: Amidon is currently employed at Boehringer Ingelheim International GmbH, where he plays a vital role in pharmaceutical research and development. His work encompasses maintaining high standards of drug formulation and delivery methods, contributing to the ongoing advancement of medical therapies.
Collaborations: Throughout his career, Gregory has collaborated with talented colleagues, including Loksidh Devi Ganorkar and John Mark Heimlich. These collaborations have facilitated the exchange of ideas and expertise, further enhancing the quality of research and innovation within the team at Boehringer Ingelheim.
Conclusion: Gregory Everett Amidon exemplifies the spirit of innovation within the pharmaceutical industry. His dedication to developing sustained-release formulations significantly contributes to patient care and treatment efficacy. With his patent and ongoing work at Boehringer Ingelheim, he continues to impact the realm of pharmaceuticals positively.